ABSTRACT: Between 1985 and 1989. many 
INTRODUCTION
Chronic myelogenous leukemia (CML) is a hematopoietic malignancy arising from neoplastic transformation of the pluripotent bone marrow stem cell. Standard findings at presentation are leukocytosis, increased granulopoiesis, sometimes increased thrombopoiesis, presence of immature granulocytic progenitors in peripheral blood, basophilia and/or eosinophilia, decreased leukocyte alkaline phosphatase (LAP), and hepatosplenomegaly. The course of the disease is biphasic. During the chronic phase, with a median duration of 1-4 years, the response to chemotherapy is usually good; D. T. Purtilo and H. L. Grierson Abbreviations: EB\,', Epshfin-l]arr virus; RFI,P, restriction fragment length polymorphism.
" Not directly associated with infc.ctious mononucleosis.
~' Six of these patients are hypogammagh)bulilaenfit:, but asymptomatic.
ciency, such as the early illness or death of males due to IM or ML are obtained from responses of families to medical-and family-history questionnaires. Files for each of the affected males and family members are maintained confidentially in the registry by kindred number. Each person is assigned a unique identification number. This information and laboratory data are stored in an IBM System/370 4381 computer (International Business Machines, Boca Raton, FL) which is accessed through several IBM and Apple (Apple Computers, Cupertineo, CA) personal computers. Data are stored and evaluated using the Statistical Analysis System (Cary, NC) [101.
Diagnosis of XLP
Each patient is assessed for the diagnostic criteria of XLP: One or more of the phenotypes (Table 1) has to occur in two or more maternally related males [2] [3] [4] . A morphological evaluation is made of slides of peripheral blood smears, surgical biopsy specimens, bone marrow, and tissues obtained at autopsy.To document the involvement of EBV, we perform a battery of tests depending on the availability of samples. Antibody titers of IgM, IgG, and IgA isotypes against viral capsid antigen (VCA) [11, 12] , early antigen (EA) [13] , and EBNA [14] are measured. We also have measured anti-EBNA titers by enzyme-linked immunosorbent assay {ELISA), using a synthetic EBNA peptide [15] . We stain available tissue imprints for EBNA [14] and probe for EBV genome using Southern blots hybridized with a cocktail of EBV DNA probes (cosmid clones 301 99 and 302-23, provided by Beverly Griffin) in DNA extracted from cryopreserved tissues obtained at autopsy or from surgical biopsy specimens [16] . We have also performed immunoblotting studies to search for EBV-encoded proteins in extracts of tissues from 15 male patients who died of IM [17] . Use of in situ hybridization techniques specific for EBV [18] permits us to identify EBV genome in archival tissues, and use of the polymerase chain reaction [19, 20] enables detection of low levels of EBV in blood [21] . hnmunoglobulin levels are quantitated in plasma by radial immunodiffusion (RID) (Kallsted, Austin, TX) or in serum by nephelometry (Beckman ICS, Brea, CA). Serum IgG subclasses are measured by RID (ICN Immunobiologicals, Lysle, IL or The Binding Site, Birmingham, England). Reference ranges for immunoglobulin levels were established froin measurements made on serum from healthy Nebraskans being evaluated for cholesterol levels (provided by our colleague, Bruce McManus, M.D., Ph.D.) and from laboratory controls. After initial evaluation of the patient, we obtain blood from pertinent family members. We measure antibody titers to EBV to seek EBV-negative males at risk for XLP. Iu addition, we measure antibody responses to EBV in women at risk of being carriers because mothers of XLP patients often have elevated antibody titers to the virus [22[ . We have also continued to pursue karyotyping of affected males and carriers in search of chromosomal abnormalities that might occur at the XLP locus [23] . Genetic analysis using DNA probes showing restriction fragment length polymorphisms to loci in the X chromosome [including DXS42, DXS37, and DXS12, which have been linked to the XLP locus} is performed as described previously [24] [25] [26] . When RFLP analysis is not informative, males at risk are challenged intravenously with bacteriophage 0X174 because males with XLP do not switch from IgM to lgG antibody production on secondary challenge with 0X174 [27. 28] .
RESULTS
Two hundred forty males with XLP within 59 unrelated kindreds had been referred to the International XLP Registry by December 1989. Among the 222 males whose fate is known, 181 (82%) have died and 41 (18%) are living. Figures 1 and 2 show the geographical locations of the families. Noteworthy is the frequent recognition of XLP in the United States, Canada, the United Kingdom, Europe, and the Mideast, and the lack of cases referred from Central and South America, Africa, the nations of the Warsaw Pact, and the highly populated countries of Asia, including China, India, Indonesia, and Japan. CML, atypical CML (aCML), and CMMoL. Not all hematologists are in agreement with these rather strict proposals, but they reflect on it anti describe their own discrilninating features for establishing the diagnosis of CML. The criteria for CML followed by the different investigators are summarized in Table 2 .
Generally, there is consensus on the most essential features, i.e., leucocytosis, basophilia, hepatosp]enomegaly, absence of absolute monocytosis, and absence of MDS or ANLL characteristics. As a consequence, the percentage of cases of Ph negative CML has been reduced from 10%-15% [2] [3] [4] to less than 5%, mainly by elimination of cases fulfilling tbe presently established criteria for CMMoL, jCML, MDS, and ANLL. Discrimination hetween Ph-positive and Ph-negative CML is not possible using clinical or helnatologic characteristics only. The remaining group of patients with Phnegative CML still appears heterogeneous and comprises cases that are clinically aud bematologically indistinguishable from Ph-positive CML, including long survival and good therapeutic response. Other cases are atypical but resemble CML more than other well defined hematologic disorders. These are designed as aCML [30, 31 I .
Cytogenetic Findings in Ph Negative CML
In 127 patients, cytogenetic studies were performed at diagnosis or during the chronic phase of CML. In 9 other patients analysis was performed after blastic transformation. During chronic phase, the karyotype was found to be normal in 48 patients (Table 3) ; abnormal in 15 cases (Table 4) ; and Ph-negative, not specifying other chromosolnal abnormalities, in 64 cases (Table 5 ). Among the 15 abnormal karyotypes, 10 showed a translocation involving chromosome 9 band q34, which is the chromosomal site involved in the Ph translocation (Table 4A ). This is highly suggestive for a variant Ph translocation, in which the microscopic aspect of chromosome 22 is not visibly altered. Molecular studies confirmed this assumption, as discussed later. The rest of this group of chronic-phase CML patients with cytogenetically abnormal karyotype showed random clonal abnormalities (Table 4B) . In a few patients, other translocations are detected, usually associated with subtypes of ANLL such as t(8;21), described by Wiedemann et al. [31] , in a patient with atypical CML (Table 4D) .
Three out of nine cases in blast crisis showed cytogenetic abnormalities (Table  4C) . Remarkably, trisomy 8 and i(17q) were found in the latter cases ]32]. These abnormalities are identical to the ones associated with blastic transformation of Phpositive CML. The resemblance between Ph-negative and Ph-positive CML is also expressed in the clonal and multipotent stem cell origin of both Ph-positive and Phnegative CML [33] and in the occurrence of lymphoid, myeloid, mixed and undifferentiated blast crisis of Ph-negative and Ph-positive CML 134, 35].
MoLecular Investigations in Ph-Negative CML
The purpose of molecular investigations in Ph-negative CML is to identify the patients with bcr-abl rearrangeineut oil DNA, RNA, or protein level. Comparison of cytogenetic, molecular, and clinical data between Ph-negative CML patients with or without bcr rearrangelnent and Ph-positive CML patients is important to determine the functional meaning of the Ph chronmsome itself. Therefore, the strategy followed by all investigators was to screen Ph-negative CML cases for: 1. The presence of BCR breakpoint using Southern blot analysis. 2. Localization of c-abl, bcr, and c-sis oncogenes on the chromosomes applying in situ hybridization techniques. 3. Expression of bcr-abl mRNA using Northern blot, RNAse protection assay, or polymerase chain reaction (PCR) techniques. Both the RNAse protection assay and PCR technique give the opportunity to identify which BCR exou is fused to abl. In CML patients with t(9:22), usually BCR exon 2 (b2) or BCR exon 3 (b3) is fused to ablexon 2 (a2), restlltingin b2a2 orb3a2 t)cr abl fusion region [36] . The results of these molecular investigations are presented in detail in Tables 3-6 together with the corresponding cytogenetic data. (An overview of these data for CML patients is provided in Table 7 .)
In summary, we can make the following points: 1) Fifty-eight out of 136 Ph-negative CML patients (including the cases in which CML diagnosis could not be verified [31] ) showed evidence of BCR rearrangement, bcr-abl mRNA expression, or the presence of a 210 kD bcr-abl protein.
2) Southern blot analysis detected a BCR breakpoint in 9 out of 10 Ph-negative CML patients with cytogenetic abnormalities involving chromosome 9 band q34, indicative for variant Ph translocation. Only one patient showed involvement of chromosome 9 band q34 without BCR rearrangement, although clinical and hematologic data were in favor of CML diagnosis [37] . However, it should be noticed that molecular data are scarce in this article: No details are mentioned about number of restriction enzyme digestions or probes used. Therefore, it cannot be ruled out that this patient also has a BCR rearrangement that was not detected in this study. When really no BCR breakpoint can be found using Southern blot analysis, it is worthwhile to search for a breakpoint more 5' in the BCR gene, e.g., using PCR technique on cDNA or pulse field gel electrophoresis (PFGE) on DNA. This case is possibly comparable with Ph-positive, BCR-negative cases that are described by Seller[ et al. [38, 39] and had a breakpoint in the first intron of the BCR gene or with the Ph-positive BCR- [55] Abbreviotion: ND. not done. ~Results in situ hybridization studies: c-abl on 12q -, 5'-bcr on 12q -, 3'-bcr on 9q +, c-sis on 22. bNo detailed molecular data presented in this article.
':Extra bands in one restriction enzyme digest only. aCML patient in which diagnosis could not be verified.
? Localization of breakpoint not mentioned. [31] "CML patient in which diagnosis could not be verified [311.
negative CML patient described by Bartram et al. [40] , which had a breakpoint in the bcr gene located 5' of the BCR region but 3' of the region described by Selleri et al. [38, 39] 3) In 20 out of 25 cases of aCML, no BCR breakpoint was detected. The five exceptions with a BCR breakpoint were all reported by the same research group [41, 42] . It would be interesting to reexamine the differential count and other clinical data to check if these patients really belong to the group of aCML or resemble more CML. To the best of our knowledge, no CMMoL or juvenile CML cases are published in which a BCR rearrangement was identified. In conclusion, bcr-abl rearrangement is strongly associated with the morphologic features of CML, although few exceptions still exist.
4) The percentage of Ph-negative CML patients with BCR rearrangement versus no BCR rearrangement varied between the different authors, e.g., Bartram et al. [32, 58] reported 3 out of 12 cases BCR-positive; Ganesan et al. [42] and Dreazen et al. 1411, 5 out of 5; Fitzgerald and Morris [46, 59] , 2 out of 2; WiedeInann et al. [31] , 8 out of 8 (5 out of 9 among the cases that were not morphologically reexamined); Kantarjian et al. [60] , 11 out of 23; and our group, 5 out of 12 [45, this report]. In our opinion, there are two main reasons responsible for these differences. First, the different authors used clinical, hematologic and morphologic criteria that are not exactly the same, resulting in differences in diagnosis. Second, some authors [41, 42] diagnosed BCR breakpoints on extra bands in only one out of several different restriction enzyme digests. In such cases, the occurrem:e of a restriction enzyme polynlorphism is a inore likely cause f()r the aberrant fragment than the l)reseo(:e of a BCR breakpoint. In such cases, additional analysis, e.g., at the protein or RNA level, is required to prove t)cr abl rearrangement.
5) Molecular data presented in Tables 3-5 indicate that several mechanisms can play a role in Ph-negative CML. A sunnnary follows.
Bcr-abl recombination takes place in the same way as in Ph-positive, CML but is cytogenetically not visible. Examples ()f complex Ph translocations in Ph-negative CML are provided by Bartram et al. I43 [, Kurzrock et al. [44] and our data [45] . In situ hybridization studies of Ph-negatiw ~, CML patients reported by Bartram el al. [43] and our own group [45] provided evidence that 5'-bcr and c-obl were localized on the same chromosomal segment. However, in these special cases, the hybrid bcr-abl gene was present on a third chromosome instead of on the Ph chromosome. In these cases, the localization of the hybrid bcr-abl gene indicated that complex Ph translocations had occurred, although the aspect of chromosome 22 was visibly unaltered.
Insertion of part of the abl gene in the bcr gene without reciprocal translocation to chromosome 9 has been described by Morris et al. [46] and Dreazen et al. [41] .
Based on investigations in a Ph-negatiw,' CML patient in which BCR was rearrange(l without juxtaposition of (:-(dJl, Bartram [47] prot)()sed the hypothesis that bcr or abl can work in combination with vet another oncogene. Thus far. there is no further evideo(:e for this hypothesis. 1) The t)reakpoint might I)e h)(:ate(t outsi(te the BCR, but within the B(]R gene as described by Se]leri e,t al. [38, 39] and Bartram eta] . [401 in Ph-positive CML cases. Both authors reported breakpoint localizati()ns more 5' in the BCtl gene.
2) Abl possibly cooperates with an as yet unknown oncogene.
3) Neither bcr nor abl are responsible for the disease in exceptional cases, but other oncogenes might be. Thus far, the few data available on this subject do not identify candidate genes for this latter hypothesis [48 54] . Recently, Cogswell et al. [55] reported that using the polymerase chain reaction very few ras mutations were detectable in CML, i.e., in 1 out ()f 18 Ph-positive CML patients in blast crisis and in 0 out of 39 Ph-positive (]NIL cases in chronic phase. However, in Ph-negative, BCR-negative atypical Cl'vlL {aCML), they [55I delnonstrate(t the presence of ras mutations in 54% (i.e.. 7/13) of the cases. This high fre, quen(:y of r(Is mutations is (:omparable with results obtained 133, Padua et al. [561 in CMMoL patients. CMMoL and aCML also share several clinical and hematoh)gi(: features. The authors therefore conclude that aCML is a subgroup of CMMol, and that both diseases belong to MDS rather than CM[,.
CONCLUSION
Correct diagnosis of CML is essential when efforts are made to (:orrelate clinical features with molecular changes in Ph-negative CML. The data reviewed in this article do not identify any clinical or hematologic (:haracteristi(: that is unique for Ph-negative CML. We expected that in nearly all Ph-negative CML patients, indistinguishable from Ph-positive CML on (:lini(:al and hematologic grounds, t)cr-abl rearrangement will be detected using molecular analysis. The data on Ph-negative CML reviewed in this article show the presence of bcr abl rearrangement in 43% of the cases (Table  7) . Although no evidence was found for bcr-abl rearrangement in the remaining 57%, in many cases no definitive proof was provided to rule out this possibility. On the other hand, it can not be denied that several CML patients are reported with classical CML disease without the presence of bcr-abl rearrangement. Very recently, this was confirmed by Kurzrock et al. [571, who reported on 11 Ph-negative, BCR-negative CML cases investigated in the MD Anderson Cancer Center using Southern and Northern blot analysis. They represented about 3% of the CML cases studied in the same period in that institute. In addition to our findings, Kurzrock et al. reported that, although the early stage of BCR-negative and BCR-positive CML shows striking resemblam:e, disease progression manifests distinctly. In the Ph-negative patients (tile aCML patients) that do not fulfill all criteria for CML, a more heterogeneous picture can be expected, showing activation of other oncogenes than bcr and abl e.g., ras, in some cases.
A controlled multicenter study of Ph-negative CML patients who are clinically, hematologically, and cytogenetically well characterized should form the basis for future molecular investigations necessary to elucidate the mechanisms responsible for Ph negative CML and to apply this knowledge to determine choice of therapy and prognosis.
